Biogen stock reports durable lupus data as Q3 date nears

Published on 10/04/2026 at 13:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen stock closed at USD 219.88 on October 2, 2026, after new litifilimab data showed 27.2 percent skin clearance at Week 52. Q3 results are set for October 28.

Bauhaus-Poster in Primärfarben mit BIOTECH-Schriftzug und geometrischen Neuronen-Illustrationen — Biogen Inc. geometrisches Bauhaus-Poster mit BIOTECH-Sektor-Text abstrakten Neuronen-Motiven auf Rastergitter ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. (ISIN US09062X1037) closed at USD 219.88 on Nasdaq on October 2, 2026, down 1.32 percent from the prior close. The key pipeline update came from 52-week litifilimab data in cutaneous lupus, released by GlobeNewswire on October 2, 2026.

Litifilimab reaches Week 52

Biogen reported that 27.2 percent of participants treated with litifilimab from the start achieved clear or almost clear skin at Week 52, compared with 19.0 percent at Week 24. The CLASI-70 measure also improved to 28.8 percent from 21.7 percent, while participants who switched from placebo saw skin improvement as early as four weeks, according to GlobeNewswire.

The Phase 2 portion evaluated 93 adults, and serious adverse events occurred in 3.4 percent of 88 participants during the extended treatment period. The Phase 3 portion remains blinded, with results planned for the first half of 2027, making the next trial readout the central pipeline checkpoint.

Q2 growth meets heavy costs

Biogen's Q2 2026 revenue rose 3.4 percent year over year to USD 2.736 billion, but net income fell 84.6 percent to USD 97.5 million and diluted EPS declined 84.8 percent to USD 0.66, according to Financial Report Insights in its Q2 2026 analysis.

The contrast matters for the pipeline story: revenue grew, but acquisition and restructuring charges compressed profitability. Biogen is therefore asking investors to weigh newer growth assets against pressure in its established multiple sclerosis franchise.

Analysts see upside

Markets Insider reported on October 2, 2026, that Needham reiterated a Buy rating with a USD 256.00 price target. The same report cited a Moderate Buy consensus and a USD 238.22 average target, representing 6.8 percent upside from the USD 220.60 reference price used in that report.

Biogen stock stays below its high

Biogen stock closed at USD 219.88 on Nasdaq on October 2, 2026, with a 52-week range of USD 138.00 to USD 230.49 and market capitalization of USD 32.5 billion. Volume was 774,024 shares.